« Back
Thrombosis Research
Concomitant use of medication with antiplatelet effects in patients receiving either rivaroxaban or enoxaparin after total hip or knee arthroplasty
To access this article, please choose from the options below
☆ Presented at: American Society of Hematology (ASH) 50th Annual Meeting and Exposition, San Francisco, CA, USA, December 6–9, 2008; European Association of Hospital Pharmacists (EAHP) 14th Congress, Barcelona, Spain, 25–27 March, 2009; 10th European Federation of National Associations of Orthopaedics and Traumatology (EFORT) Congress, Vienna, Austria, June 3–6, 2009; International Society on Thrombosis and Haemostasis (ISTH) XXII Congress, Boston, MA, USA, July 11–16, 2009; and American Academy of Orthopaedic Surgeons (AAOS) 2010 Annual Meeting, New Orleans, LA, USA, March 9–13, 2010.
PII: S0049-3848(11)00655-4
doi: 10.1016/j.thromres.2011.12.005
« Back
Thrombosis Research
